Can herbs or natural remedies treat Lyme disease?

When an infected Ixodes tick attaches to skin and feeds for at least 24–36 hours, Borrelia burgdorferi spirochetes migrate from the tick's gut into the bloodstream and skin². The bacterium is a corkscrew-shaped spirochete that drills through tissue using flagella tucked inside its outer membrane, which lets it slip into joints, nerves, and the central nervous system within days to weeks². The classic early sign is erythema migrans — an expanding red rash at the bite site, appearing 3 to 30 days later. About 70–80% of people develop it, but only a minority show the textbook bullseye pattern; most rashes are uniformly red². Flu-like symptoms — fatigue, fever, headache, muscle aches, swollen lymph nodes — often accompany the rash.

If untreated, weeks to months later the infection can disseminate, producing facial palsy, meningitis-like headaches, heart block, and large-joint arthritis (most often the knee)².

What Standard Treatment Looks Like

The 2020 IDSA/AAN/ACR guidelines remain the consensus standard of care²:

• Early Lyme with erythema migrans: doxycycline 100 mg twice daily for 10 days (preferred), or amoxicillin 500 mg three times daily for 14 days
• Lyme arthritis: a 28-day oral course of doxycycline or amoxicillin
• Neurologic Lyme (meningitis, radiculopathy): oral doxycycline; IV ceftriaxone reserved for parenchymal CNS involvement
• Lyme carditis with high-grade heart block: IV ceftriaxone, transitioning to oral once the block resolves

The guidelines also recommend a single 200 mg dose of doxycycline within 72 hours of removing an attached high-risk Ixodes tick as post-exposure prophylaxis². They explicitly do not recommend prolonged or repeated antibiotic courses for persistent post-treatment symptoms². Randomized trials of longer antibiotic courses for persistent symptoms found either no benefit over placebo or only limited gains, with treatment-related adverse events reported in some^8,9,10,11.

Prevention Is the Highest-Leverage Move

Once Lyme is established, treatment outcomes get harder. Prevention is where most of the leverage lives:

• Permethrin-treated clothing. A randomized trial with two years of follow-up in 159 outdoor workers found factory-impregnated permethrin uniforms cut work-related tick bites by 82% in year 1 and 34% in year 2, though the year-2 estimate was statistically uncertain⁴. The authors concluded the uniforms were highly effective for at least 1 year, on top of the usual tick bite prevention measures workers already used.
• EPA-registered skin repellents. DEET (20–30%), picaridin (20%), IR3535, oil of lemon eucalyptus, and 2-undecanone are all CDC-listed for tick repellency.
• Tick checks within 2 hours of coming inside, showering soon after, and tossing clothes in a hot dryer for 10 minutes (which kills ticks more effectively than washing).
• Prompt removal with fine-tipped tweezers, pulling steady and straight from the skin — most transmission requires 24+ hours of attachment.

For yard management, keep grass short, create a 3-foot mulch barrier between lawn and woods, and discourage deer browsing near the house.

What the Research on Botanicals Actually Shows

Many people with persistent symptoms turn to herbs. The most relevant lab evidence comes from the Johns Hopkins group (Feng, Zhang, and collaborators), which has systematically screened botanicals against B. burgdorferi — including its dormant "stationary phase" cells that don't respond to standard antibiotics^5,6,7.

The standouts in their 2020 Frontiers in Medicine screen⁵:

• Cryptolepis sanguinolenta — at 1% extract, the only single agent that completely eradicated stationary-phase B. burgdorferi in subculture testing — outperforming doxycycline and cefuroxime in this assay
• Polygonum cuspidatum (Japanese knotweed, a key resveratrol source) — strong activity against both growing and non-growing forms. See our Japanese knotweed page for more.
• Uncaria tomentosa (cat's claw), Artemisia annua, Juglans nigra (black walnut), Cistus incanus, and Scutellaria baicalensis — meaningful activity but not full eradication

In separate essential-oil screens, garlic bulb oil, allspice, myrrh, and litsea completely killed stationary-phase B. burgdorferi at just 0.1% concentration⁷, and oregano, cinnamon bark, and clove bud essential oils showed strong activity at 0.05%⁶.

Important caveat: all of this is in-vitro test-tube work. There are no published randomized trials in humans showing that any of these botanicals cure Lyme disease, and reaching the concentrations that work in a petri dish through oral dosing is biologically uncertain. The lab data is a starting point for further research, not a treatment recommendation. Botanical regimens are best used alongside — not in place of — guideline-based antibiotic therapy and under the supervision of a clinician familiar with tick-borne disease.

Living With Post-Treatment Lyme Disease Syndrome

Roughly 10–20% of treated people experience PTLDS — fatigue, widespread pain, sleep disturbance, and cognitive complaints that persist beyond 6 months³. Randomized trials of additional antibiotics have found either no benefit over placebo or only limited gains^8,9,10,11. Helpful adjuncts that have evidence in overlapping conditions include pacing strategies for fatigue, low-histamine eating patterns when mast-cell-like flushing or food reactions are prominent (see our mast cell activation syndrome page), gentle movement (yoga, walking, tai chi), prioritizing deep sleep, and addressing co-existing conditions like sleep apnea, vitamin D deficiency, and gut dysbiosis. Working with a Lyme-literate physician matters because PTLDS often overlaps with chronic fatigue syndrome, fibromyalgia, dysautonomia (POTS), and small-fiber neuropathy — each of which has its own targeted approaches.

Disease burden (Kugeler 2021). Using a large commercial insurance claims database covering 2010–2018, Kugeler and colleagues at the CDC estimated that approximately 476,000 Americans are diagnosed and treated for Lyme disease annually — roughly 18-fold higher than the 24,000–35,000 cases captured by national surveillance each year¹. The diagnosis rate was highest in children aged 5–9 and adults aged 65–74, with strong regional concentration in the Northeast and upper Midwest. The gap between surveillance reports and treated cases reflects both under-reporting and presumed over-treatment of look-alike conditions, but the order of magnitude makes Lyme one of the more common bacterial infections in the United States.

Standard of care (Lantos et al. 2021). The IDSA/AAN/ACR 2020 guidelines, published in Clinical Infectious Diseases in January 2021, were developed by a 35-member multidisciplinary panel using GRADE methodology across 43 clinical questions². Key evidence-graded recommendations: a single 200 mg dose of doxycycline as post-exposure prophylaxis within 72 hours of high-risk tick removal (strong recommendation, high-quality evidence); 10 days of doxycycline for erythema migrans (strong, moderate); 28 days of oral doxycycline for Lyme arthritis (strong, moderate); and a strong recommendation against prolonged antibiotic courses for persistent post-treatment symptoms. Randomized trials of longer antibiotic courses for persistent symptoms found either no benefit over placebo or only limited gains. Klempner et al. (2001) ran two trials, in 78 seropositive and 51 seronegative patients, comparing 30 days of IV ceftriaxone followed by 60 days of oral doxycycline with placebo, and found no significant difference in outcomes⁸. Krupp et al. (2003) randomized 55 patients with persistent severe fatigue to 28 days of IV ceftriaxone or placebo; fatigue improved with ceftriaxone but cognitive function did not, and the authors concluded that the study did not support additional parenteral ceftriaxone⁹. Fallon et al. (2008) randomized 37 patients with Lyme encephalopathy to 10 weeks of IV ceftriaxone or placebo; the cognitive improvement seen at week 12 was not sustained to week 24, and adverse events from the study medication or the PICC line occurred in 6 of 23 patients given ceftriaxone and 1 of 14 given placebo¹⁰. Berende et al. (2016) randomized 281 patients to 12 weeks of oral doxycycline, clarithromycin plus hydroxychloroquine, or placebo (after 2 weeks of open-label IV ceftriaxone) and found no additional benefit for health-related quality of life¹¹.

Post-treatment Lyme disease syndrome (Aucott 2015). Aucott's review in Infectious Disease Clinics of North America synthesizes the prospective cohort data establishing PTLDS as a real clinical entity³. In Aucott's Johns Hopkins SLICE cohort, 36% of acutely diagnosed patients reported new-onset fatigue at 6 months post-treatment, 20% reported widespread pain, and 45% reported neurocognitive difficulties — substantially higher than matched controls. Risk factors included delayed initial diagnosis and disseminated disease at presentation. Aucott notes that serology is poorly suited to confirming PTLDS, since IgG antibodies persist for years after successful clearance and don't correlate with active infection. The mechanism remains debated — autoimmunity, residual antigen, persistent infection in privileged sites, and post-infectious dysautonomia have all been proposed but not definitively established.

Permethrin RCT (Vaughn et al. 2014). This double-blind randomized controlled trial in American Journal of Preventive Medicine, run between March 2011 and September 2012, randomized 159 volunteer outdoor workers from North Carolina's state divisions of forestry, parks and recreation, and wildlife; 127 and 101 completed the first and second years of follow-up⁴. The intervention group received factory-impregnated long-lasting permethrin uniforms; control uniforms received a sham treatment, and everyone kept using their usual tick bite prevention measures. Protective effectiveness against work-related tick bites was 0.82 (95% CI 0.66–0.91) in year 1 and 0.34 (95% CI −0.67 to 0.74) in year 2, so the year-2 estimate could not be distinguished from no effect. The authors concluded that the uniforms were highly effective for at least 1 year in deterring tick bites, in the context of the typical tick bite prevention measures outdoor workers use.

Botanical screen (Feng et al. 2020). The Johns Hopkins group screened 14 botanical extracts from a panel commonly used by Lyme-literate practitioners against both log-phase and stationary-phase B. burgdorferi B31 strain⁵. Stationary-phase cultures are the in-vitro proxy for the dormant "persister" cells that survive standard antibiotic exposure. Of the 14 extracts, 7 showed meaningful activity (≥90% reduction at 1%): Cryptolepis sanguinolenta, Polygonum cuspidatum, Juglans nigra, Artemisia annua, Uncaria tomentosa, Cistus incanus, and Scutellaria baicalensis. In 21-day subculture testing — the strictest test for true sterilization — only 1% Cryptolepis sanguinolenta completely eradicated the bacteria with no regrowth; doxycycline and cefuroxime at clinically relevant concentrations did not. Notably, Stevia rebaudiana, andrographis, grapefruit seed extract, ashwagandha, and colloidal silver showed little activity in this assay. The authors are explicit that these are screening assays and that animal and human pharmacokinetics, dosing, and clinical trials remain to be done.

Essential oil screens (Feng et al. 2017, 2018). In the 2017 Frontiers in Medicine study, 34 essential oils were tested at 0.25–0.5% against stationary-phase B. burgdorferi⁶. Oregano, cinnamon bark, clove bud, citronella, and wintergreen oils showed the strongest activity; oregano and cinnamon bark completely eradicated viable cells without regrowth in subculture at 0.05%. The active fraction in cinnamon was identified as cinnamaldehyde and in oregano as carvacrol. The follow-up 2018 Antibiotics paper screened an additional 35 oils and found garlic (Allium sativum) bulb oil, allspice (Pimenta officinalis), myrrh, and litsea cubeba completely sterilized stationary-phase cultures at just 0.1%⁷. Mechanistically, these oils appear to disrupt cell membranes and biofilm matrices — pathways that standard ribosomal antibiotics like doxycycline can't access in dormant cells.

Strength of evidence — a frank assessment. The disease-burden, prevention, and standard-of-care evidence is robust: large datasets, validated trials, and consensus across infectious disease societies. The botanical evidence is one tier lower: the in-vitro studies are well-executed and the eradication of persisters is striking, but they have not been replicated in animal models of established infection or in any human RCT. People reporting symptomatic improvement on Cryptolepis or Japanese knotweed protocols may be experiencing real benefit, the natural waning of post-infectious inflammation, or placebo — current evidence cannot distinguish these. The honest summary: get treated promptly with guideline-based antibiotics, prioritize prevention, and treat botanical protocols as experimental adjuncts with promising but unfinished science.